Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Date:11/6/2007

CAMBRIDGE, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2007. At September 30, 2007, Idenix's cash, cash equivalents and marketable securities totaled approximately $136.5 million.

For the third quarter ended September 30, 2007, Idenix reported total revenues of $10.9 million, compared with total revenues of $19.6 million in the third quarter of 2006. Total revenues for the third quarter of 2007 consist of reimbursement by Novartis Pharma AG of expenses incurred by Idenix in connection with the development of Tyzeka(R)/Sebivo(R) (telbivudine), valtorcitabine and valopicitabine, Idenix's product and product candidates for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV), respectively, and the amortization of the up-front fees received by Idenix in connection with Novartis' license of telbivudine, valtorcitabine and valopicitabine and product sales of Tyzeka/Sebivo. Idenix reported a net loss of $30.5 million, or a loss of $0.54 per basic and diluted share for the third quarter ended September 30, 2007, compared to a net loss of $19.7 million, or a loss of $0.35 per basic and diluted share for the third quarter ended September 30, 2006. Included in the net loss for the third quarter ended September 30, 2007 was a $6.4 million restructuring charge primarily related to severance costs and impairment of certain fixed assets related to the transition of commercialization, development and manufacturing activities for telb
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Some obese people have a genetic mutation that ... brains when they see food, researchers report. Gaining ... of pleasure and gratification at the sight of high-calorie ... prevent overeating, the scientists suggested. More than one-third ... caused by a combination of overeating, a lack of ...
(Date:7/30/2014)... July 30, 2014. A new network of 25 regional ... Trials Network (NIH StrokeNet) is working to change ... Despite advances of the last two decades, stroke ... causes death or disability for 795,000 Americans. The numbers ... the population. , To accelerate the pace of ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased to ... will serve as chair. The board was voted upon ... Conference in Houston, Texas July 10-12. , “The ... us. From the rollout of the first EDNF Center ... Medical Center to our September physicians conference to a ...
(Date:7/30/2014)... July 30, 2014 As the controversy ... in gynecological surgeries continues to grow, Bernstein Liebhard LLP ... those calling for a ban on uterine morcellation. According ... was diagnosed with leiomyosarcoma following a hysterectomy that involved ... of her diagnosis, the aggressive cancer had progressed to ...
(Date:7/30/2014)... 30, 2014 Hospitals continually face ... of care that their practitioners provide. During a ... Rowe, discussed the importance of establishing effective peer ... performance and quality of care. , With ... Mr. Rowe elaborated on setting performance expectations, conducting ...
Breaking Medicine News(10 mins):Health News:Gene Mutation May Make Food More Tempting 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3
... , BUFFALO, N.Y., July 15 CTG (Nasdaq: ... company, announced today that it was named by Healthcare Informatics ... providers, the Healthcare Informatics 100 (HCI 100). CTG was named to ... healthcare provider market. In addition to other large healthcare IT consulting ...
... , , DALLAS, ... Enterprises, LLC announced today that the company has been awarded ... Medicaid Services (CMS) to serve as the Medicare Administrative Contractor ... The full period of contract performance is five years, including ...
... WOODCLIFF LAKE, N.J., July 15 Par Pharmaceutical Companies, Inc. (NYSE: ... live webcast on Tuesday, August 4, 2009 at 9:00 am EDT to review ... its financial results on August 4 before the market opens. The earnings release ... , , Access to the live webcast can ...
... , , NAPLES, Fla., July 15 ... parents, has gathered the top ten issues that affect caregivers. These issues ... ( www.agingcare.com/Community ), where caregivers connect and communicate with one ... paid for caregiving. Oftentimes, adult children have to give up their ...
... July 15 The overall OTC market grew 3.2% during non-recession ... Impact of Recessions on the U.S. OTC Market ... , The impact of recessions on ... by private-label products and is reflected in slower growth rates. The ...
... the way for future targeted treatment, , WEDNESDAY, July ... cells appear to be important predictors of the spread ... measured levels of circulating endothelial cells and endothelial progenitor ... with metastatic cancer and 20 healthy children. Circulating endothelial ...
Cached Medicine News:Health News:CTG Named to Healthcare Informatics Annual Ranking of the Top 100 Healthcare IT Providers 2Health News:CTG Named to Healthcare Informatics Annual Ranking of the Top 100 Healthcare IT Providers 3Health News:CMS Selects TrailBlazer Health Enterprises to Administer Medicare Program in Arkansas, Louisiana and Mississippi 2Health News:Caring for Elderly Parents Is Tougher During Hard Times 2Health News:OTC Market Is Not Largely Impacted by Recession; However, Prominent Growth Remains Only in Some Categories, According to Kline 2Health News:Rare Cells Linked to Pediatric Cancers 2
(Date:7/30/2014)... , July 30, 2014 Reportlinker.com ... available in its catalogue: mHealth and ... http://www.reportlinker.com/p0356852/mHealth-and-Home-Monitoring-–-6th-Edition.html Executive summary ... delivered, leading to better outcomes, decreased costs and ... for mHealth solutions is still in an early ...
(Date:7/30/2014)... and KISSING, Germany , ... distributor of a single use and computer-assisted ("robotic") colonoscopy ... Shamir , a worldwide recognized medical device executive, as ... Mr. Shamir is a highly respected global visionary ... assignment he served as President and Chief Executive Officer ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Eisai ... announced today that an article based on post-hoc analyses from ... Weight Loss While on Lorcaserin, Diet, and Exercise as a ... the online issue of Obesity , the official peer ... analyses was to identify whether there is an early treatment ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Calif., Jan. 16 Cerimon,Pharmaceuticals, Inc., announced today ... clinical studies of its once-,daily topical diclofenac sodium ... the studies, designated the "SUPPORT" (Stop Underlying Pain ... will assess the,efficacy and safety of Cerimon,s patch ...
... Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced that ... with the first patient being treated on January ... evaluate the safety, tolerability and,pharmacokinetic profile of SGX523, ... cMET receptor tyrosine,kinase., The Phase I clinical ...
Cached Medicine Technology:Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 2Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain 3SGX Initiates Phase I Trials for SGX523 2SGX Initiates Phase I Trials for SGX523 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: